Additionally, combining PP2A activators or CIP2A inhibitors with kinase inhibitors (e.g., MEK inhibitors) or chemotherapy enhances anticancer effects, particularly in aggressive cancers like lung cancer [143]. Here, CIP2A is linked to lung carcinoma.